• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Cdk4/6 Inhibitor IV

CAS No. 359886-84-3

Cdk4/6 Inhibitor IV ( —— )

产品货号. M21881 CAS No. 359886-84-3

Cdk4/6 抑制剂 IV 是一种细胞渗透性三氨基嘧啶,可逆地阻断 Cdk4/cyclin D1 和 Cdk6/cyclin D1 活性,IC50 值分别为 1.5 和 5.6 μM。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥1264 有现货
10MG ¥2005 有现货
25MG ¥3990 有现货
50MG ¥5543 有现货
100MG ¥7371 有现货
200MG ¥9720 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    Cdk4/6 Inhibitor IV
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Cdk4/6 抑制剂 IV 是一种细胞渗透性三氨基嘧啶,可逆地阻断 Cdk4/cyclin D1 和 Cdk6/cyclin D1 活性,IC50 值分别为 1.5 和 5.6 μM。
  • 产品描述
    Cdk4/6 inhibitor IV is a cell-permeable triaminopyrimidine that reversibly blocks Cdk4/cyclin D1 and Cdk6/cyclin D1 activity with IC50 values of 1.5 and 5.6 μM, respectively.It demonstrates potent selectivity for Cdk4/6 over Cdk5/p35, v-abl, c-met, IGF-1R, insulin receptor, Cdk2/cyclin A, Cdk2/cyclin E, Cdk4/cyclin D2, Cdk6/cyclin D2, and Cdk1/cyclin B (IC50s = > 10-100 μM).At 5-10 μM, this compound blocks retinoblastoma protein phosphorylation at Ser780 and Ser795, inducing cell cycle arrest in the G1 phase and apoptosis in asynchronous cell lines.In mice bearing human HCT116 colon carcinoma xenografts, 30 mg/kg, i.p. Cdk/6 inhibitor IV suppressed tumor growth after 29 days of treatment.
  • 体外实验
    GP-82996 (5, 10 μM; 24 hours) induces G1 arrest and G0-G1/S ratio increase in U2OS (p16 negative) and MRC-5 (p16 positive) cells.GP-82996 (5, 10 μM; 24 hours) reduces hyperphosphorylation of pRb, but has no changes in the levels of CDK4 in U2OS, MRC-5 cells.GP-82996 (5, 10 μM; 48 hours) induces aooptosis in 83% of U2OS cells in concentration of 10μM.GP-82996 (0.1-40 μM; 24,48, 72 hours) inhibits the cell proliferation of A549, H358, SKLU-1, H23, PC14 cells with IC50 values of 72 h are 4-7 μM.GP-82996 (3, 5, 10 μM; 48 hours) induces G1 arrest in A549 and H23 cells.GP-82996 ((1, 3, 5, 10 μM; 72 hours) enhances Paclitaxel sensitivity in KRAS mutation-bearing lung cancer cells (A549, SKLU-1, H23 cells) .GP-82996 (10 μM; 72 hours) combined with Paclitaxel (3 nM; 72 hours) increases the apoptosis of A549 and H23 cells.
  • 体内实验
    GP-82996 (30 mg/kg, i.p. for 29 days) shows smaller final tumor volume compared with vehicle control in mouse xenograft models. Animal Model:19-21 g female BALB/c nu/nu mice xenograft model (HCT116 tumors volume=100 mm3)Dosage:30 mg/kg Administration:i.p. every 12 hours for 29 days Result:Showed smaller final tumor volume compared with vehicle control in mouse xenograft models.
  • 同义词
    ——
  • 通路
    Others
  • 靶点
    Other Targets
  • 受体
    ——
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    359886-84-3
  • 分子量
    456.6
  • 分子式
    C27H32N6O
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMF: 30 mg/ml;DMSO: 30 mg/ml;DMSO:PBS(pH 7.2) (1:4): 0.2 mg/ml;Ethanol: 1 mg/ml
  • SMILES
    CCNC1=NC(NC2=CC=C(N(CC3=CC=CC=C3)C=C4)C4=C2)=NC(N[C@H]5CC[C@H](O)CC5)=C1
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Soni R, O'Reilly T, Furet P, et al. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4[J]. Journal of the National Cancer Institute, 2001, 93(6): 436-446.
产品手册
关联产品
  • RMC-6291

    RMC-6291 是一种口服有效的 KRASG12C(ON) 共价抑制剂。RMC-6291 在 KRASG12C(ON) 和亲环蛋白 A (CypA) 之间的肿瘤细胞内形成三复合物。因此,RMC-6291 通过空间阻断 RAS 效应子结合来阻止 KRASG12C(ON) 发出信号。RMC-6291 在 KRASG12C 肿瘤模型中对 RAS 通路活性产生了深度和持久抑制。

  • Diclofenac Amide

    用作双氯芬酸的中间体。

  • Synaptobrevin-2 (75-...

    Synaptobrevin-2 (75-78) (human, bovine, mouse, rat)